END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate activity and toxicity of the combination of
carboplatin and liposomal doxorubicin as first-line chemotherapy of patients with advanced or
recurrent endometrial carcinoma.